Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0843
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer ; volume:80 ; number:6 ; day:11 ; month:8 ; year:2017 ; pages:1063-1072 ; date:12.2017
Cancer chemotherapy and pharmacology ; 80, Heft 6 (11.8.2017), 1063-1072, 12.2017
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Matsubara, Nobuaki
- Beteiligte Personen und Organisationen
-
Mukai, Hirofumi
Hosono, Ako
Onomura, Mai
Sasaki, Masaoki
Yajima, Yoko
Hashizume, Kensei
Yasuda, Masanobu
Uemura, Miho
Zurth, Christian
SpringerLink (Online service)
- DOI
-
10.1007/s00280-017-3417-3
- URN
-
urn:nbn:de:1111-201801134222
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Matsubara, Nobuaki
- Mukai, Hirofumi
- Hosono, Ako
- Onomura, Mai
- Sasaki, Masaoki
- Yajima, Yoko
- Hashizume, Kensei
- Yasuda, Masanobu
- Uemura, Miho
- Zurth, Christian
- SpringerLink (Online service)
Ähnliche Objekte (12)
An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
Ureter metastatic castration-resistant prostate cancer: a case report
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Appropriate definition of non-metastatic castration-resistant prostate cancer (nmCRPC) and optimal timing of androgen receptor signaling inhibitor (ARSI)
Analysis of regulation of angiogenesis by androgen receptor ligands in castration-resistant prostate cancer
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
Ureter metastatic castration-resistant prostate cancer: a case report
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Appropriate definition of non-metastatic castration-resistant prostate cancer (nmCRPC) and optimal timing of androgen receptor signaling inhibitor (ARSI)
Analysis of regulation of angiogenesis by androgen receptor ligands in castration-resistant prostate cancer
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
Ureter metastatic castration-resistant prostate cancer: a case report
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Appropriate definition of non-metastatic castration-resistant prostate cancer (nmCRPC) and optimal timing of androgen receptor signaling inhibitor (ARSI)
Analysis of regulation of angiogenesis by androgen receptor ligands in castration-resistant prostate cancer